Insight Molecular Diagnostics Inc. Ordinary Shares IMDX 深 沪
已收盘 11-07 16:00:00 美东时间
6.24
-0.260
-4.00%
华盛通- 最 高6.49
- 今 开6.48
- 成交量 7.99万股
- 最 低 6.12
- 昨 收 6.50
- 总市值 1.79亿
- 52周最高 6.79
- 市盈率 静 --
- 换手率 0.28%
- 52周最低 1.922
- 委 比 -66.67%
- 总股本 2861.97万
- 历史最高 204.80
- 量 比 1.55
- 振 幅 5.69%
- 历史最低 1.922
- 每 手 1
- 风险率 0.94%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多A Look at Insight Molecular's Upcoming Earnings Report
Insight Molecular (NASDAQ:IMDX) is gearing up to announce its quarterly earning...
今天 04:04
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch
Insight Molecular Diagnostics Inc. (iMDx) announced the appointment of Steven Tahmooressi as Vice President of Marketing. He brings over 25 years of experience in new product adoption across transplantation, oncology, and immunology. Tahmooressi will lead global marketing efforts for the GraftAssure family of assays and future products. iMDx is preparing to launch its first clinical kitted assay, GraftAssureDx, in 2026. The company aims to expand...
10-13 20:05
Insight Molecular Diagnostics Publishes GraftAssure Study In AJT, Demonstrates Assay's Value In Monitoring High-Risk Kidney Transplant Patient
American Journal of Transplantation study positions GraftAssure as potentially essential in managing immunosuppression treatment in kidney transplant patients with certain cancersGraftAssure used to help avoid
10-06 19:20
iMDx Reports Kidney Transplant Patient Achieved ‘Immune Reset’ with Novel Therapy and GraftAssure Monitoring
A study published in the American Journal of Transplantation highlights the essential role of GraftAssure in managing kidney transplant patients with certain cancers, particularly in avoiding overtreatment and preserving immune function. The study details a unique case where GraftAssure molecular testing confirmed the absence of organ rejection during novel CD19 CAR-T therapy for a patient with lymphoma, enabling sustained graft health and oncolo...
10-06 11:15
Insight Molecular Diagnostics Extends Executive Employment Agreement
Insight Molecular Diagnostics ( ($IMDX) ) just unveiled an update. On September...
10-03 04:35
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
InspireMD announced inducement grants of 88,324 restricted shares to five new non-executive employees outside its 2021 Equity Incentive Plan under the 2024 Inducement Plan. The grants vest over three years, with one-third vesting annually on the first, second, and third anniversaries, contingent on continued employment.
09-25 20:05
Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando
Insight Molecular Diagnostics Inc. (iMDx) will present its GraftAssureIQ research-use-only test kit and discuss the clinical potential of its GraftAssure technology at two major conferences. At the IATDMCT annual meeting in Singapore, the company will host a symposium on September 24 to highlight how GraftAssureIQ can improve transplant rejection detection and treatment monitoring. In Orlando, iMDx and its partner Bio-Rad will present on October ...
09-24 11:05
Insight Molecular Diagnostics Approves Executive Salary Increases
Insight Molecular Diagnostics ( ($IMDX) ) just unveiled an announcement. On Sep...
09-20 04:36
Insight Molecular Diagnostics Enrolls Patients In Its Clinical Trial To Assess GraftAssureDx
iMDx's ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026NASHVILLE, Tenn., Sept. 08, 2025
09-08 19:07
Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database
- iMDx launches a new registry enrolling 5,000 kidney transplant patients across 25 centers to gather real-world data on its rejection assay. - The study aims to validate a "combined score" algorithm for donor-derived cell-free DNA (dd-cfDNA) and assess the Berlin Protocol for high-risk patients. - Over three years, approximately 50,000 samples will be collected. - The registry complements iMDx’s kit-based testing strategy and supports future in-...
09-08 11:15
